<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02598869</url>
  </required_header>
  <id_info>
    <org_study_id>00011584</org_study_id>
    <nct_id>NCT02598869</nct_id>
  </id_info>
  <brief_title>Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema</brief_title>
  <official_title>Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema (CME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Macular edema is the most common sight threatening complication of uveitis which can lead to&#xD;
      permanent loss of central vision. Triamcinolone acetonide ( the study drug)injection for&#xD;
      treatment of cystoid macular edema(CME) is well established. The purpose of this study is to&#xD;
      compare the safety and efficacy of injecting the study drug inside the eye(intravitreal&#xD;
      injection) and behind the eye(subtenon injection)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is randomized interventional non inferiority study that will enroll 30 adults aged&#xD;
      18 or older with the diagnosis of cystoid macular edema secondary to non-infectious uveitis.&#xD;
      Potential subjects will be recruited from the retina and uveitis clinics at the Casey Eye&#xD;
      Institute, Oregon health and science University(OHSU). Potential recruits will be asked to&#xD;
      sign and date the informed consent and a copy will be given to subject prior to any study&#xD;
      procedure. Subjects will have a screening visit before the injection procedure so that the&#xD;
      study doctor can decide if they meet the criteria to be in the study. This study requires 6&#xD;
      visits to the clinic and will take 6 months to complete. During the screening visit, medical/&#xD;
      surgical/ ocular history and will be collected from the subject and medical records.&#xD;
      Laboratory tests will be performed to rule out infectious uveitis if the subject has not&#xD;
      already had infectious types of uveitis ruled out since the time of diagnosis of uveitis.&#xD;
      Urine collection for pregnancy test for females of childbearing potential will be done.&#xD;
      Examination of subjects will include measurement of visual acuity, examination of the front&#xD;
      and back part of the eye, measurement of the eye pressure . A scan of the retina will be&#xD;
      obtained by spectral domain optical coherence tomography (SD-OCT). During the injection&#xD;
      visit, history, examination, and pregnancy tests will be repeated in addition to receiving&#xD;
      the injection. Subjects will be randomized to either injecting the study drug by intravitreal&#xD;
      or subtenon routes. Examination after injection will be performed to rule out immediate&#xD;
      complications. Then subjects will have 4 follow-up visits (2 weeks, 1 month, 3 months and 6&#xD;
      months). During each visit, subjects will be asked about adverse events, concomitant&#xD;
      medications, how their eyes feel in addition to obtaining a clinical examination and OCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Actual">November 30, 2015</start_date>
  <completion_date type="Actual">May 15, 2016</completion_date>
  <primary_completion_date type="Actual">May 15, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in best corrected visual acuity( BCVA)</measure>
    <time_frame>at 1,3 and 6 months after intervention</time_frame>
    <description>Best corrected visual acuity will be assessed using the Snellen chart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in central macular thickness in micrometers</measure>
    <time_frame>at 1,3 and 6 months after intervention</time_frame>
    <description>A spectral domain optical coherence tomography device will be used to capture central macular thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of eyes that develop side effects</measure>
    <time_frame>at 1,3 and 6 months after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Uveitis</condition>
  <condition>Cystoid Macular Edema</condition>
  <arm_group>
    <arm_group_label>Intravitreal triamcinolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects will receive intravitreal injection of 2mg /0.05 ml of preservative free triamcinolone acetonide ( otherwise known as triesence)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>posterior subtenon triamcinolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects will receive posterior subtenon injection of 40mg /1 ml of preserved triamcinolone acetonide ( otherwise known as kenalog)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <description>injection of triamcinolone acetonide</description>
    <arm_group_label>Intravitreal triamcinolone</arm_group_label>
    <arm_group_label>posterior subtenon triamcinolone</arm_group_label>
    <other_name>triesence</other_name>
    <other_name>kenalog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant female at least 18 years of age at the time of consent&#xD;
&#xD;
          -  One or both eyes having CME associated with non-infectious uveitis&#xD;
&#xD;
          -  Subject has the ability to understand and sign the Informed Consent Form&#xD;
&#xD;
          -  Subject is willing and able to comply with scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to triamcinolone acetonide&#xD;
&#xD;
          -  History of any type of non-infectious uveitis without macular edema&#xD;
&#xD;
          -  Vitreous hemorrhage&#xD;
&#xD;
          -  Uveitis with infectious etiology&#xD;
&#xD;
          -  CME due to non-uveitis causes&#xD;
&#xD;
          -  Previous viral retinitis or uveitis&#xD;
&#xD;
          -  Toxoplasmosis scar in study eye or scar related to viral retinitis&#xD;
&#xD;
          -  Media opacity interfering with optical coherence tomography (OCT) or evaluation of the&#xD;
             retina and vitreous&#xD;
&#xD;
          -  Patient may not have had prior treatment for CME within the past 3 months including&#xD;
             anti-VEGF (vascular endothelial growth factor), periocular or intravitreal steroid&#xD;
&#xD;
          -  Pregnant or nursing women; females of childbearing potential who are unwilling or&#xD;
             unable to use an acceptable method of contraception&#xD;
&#xD;
          -  Subjects unwilling to comply with the study protocol or who are likely to be lost to&#xD;
             follow-up within 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Guex-Crosier Y. The pathogenesis and clinical presentation of macular edema in inflammatory diseases. Doc Ophthalmol. 1999;97(3-4):297-309. Review.</citation>
    <PMID>10896343</PMID>
  </reference>
  <reference>
    <citation>Sivaprasad S, McCluskey P, Lightman S. Intravitreal steroids in the management of macular oedema. Acta Ophthalmol Scand. 2006 Dec;84(6):722-33. Review.</citation>
    <PMID>17083528</PMID>
  </reference>
  <reference>
    <citation>Leder HA, Jabs DA, Galor A, Dunn JP, Thorne JE. Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. Am J Ophthalmol. 2011 Sep;152(3):441-448.e2. doi: 10.1016/j.ajo.2011.02.009. Epub 2011 Jun 8.</citation>
    <PMID>21652023</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <last_update_submitted>February 5, 2019</last_update_submitted>
  <last_update_submitted_qc>February 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Phoebe Lin, MD,PhD</investigator_full_name>
    <investigator_title>Assistant professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Triamcinolone acetonide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

